

VentriPoint to Present at the 2012 Aegis Healthcare Conference
September 26, 2012 07:00 ET
VentriPoint to Present at the 2012 Aegis Healthcare Conference
SEATTLE, WASHINGTON--(Marketwire - Sept. 26, 2012) - VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (OTCQX:VPTDF) is pleased to announce that Dr. George Adams, CEO of VentriPoint, will provide an overview of the Company's business during his live presentation and will be participating in one-on-one meetings with investors, analysts and industry executives.
Event: 2012 Aegis Healthcare Conference |
Date: Saturday, September 29, 2012 |
Time: 11.45 am (Pacific Time) |
Location: The Wynn, Las Vegas, NV |
Those interested in a one-on-one meeting are encouraged to contact Dr. Adams at [ gadams@ventripoint.com ].
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ diagnostic tool and is pursuing the US-FDA approval through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.